Motyl T, Traczyk Z, Holska W, Daniewska-Michalska D, Cieśluk S, Kukulska W, Kałuzny Z, Podgurniak M
Department of Animal Physiology, Veterinary Faculty, Warsaw Agricultural University, Poland.
Eur J Clin Chem Clin Biochem. 1993 Apr;31(4):205-9. doi: 10.1515/cclm.1993.31.4.205.
The HPLC method for the simultaneous determination of urinary neopterin, pseudouridine, and creatinine allows a rapid evaluation of the activation state of cell-mediated immunity, and the stimulation of whole-body rRNA + tRNA turnover, associated with malignant growth. Urinary neopterin and pseudouridine concentrations in healthy subjects amounted to: 106.6 +/- 34.6 mumol/mol creatinine, and 19.6 +/- 5.2 mmol/mol creatinine (mean +/- SD), respectively. The increase of neopterin excretion in patients with haematological neoplasms ranged from 146% in Hodgkin's disease to 534% in non-Hodgkin's lymphoma, whereas the increase in cancer cases ranged from 95% in adenocarcinoma of the gaster to 741% in hepatocellular carcinoma. The changes in pseudouridine excretion were much less pronounced: 63% in non-Hodgkin's lymphoma and 120% in carcinoma of the urinary bladder. The correlation coefficient between neopterin and pseudouridine was relatively low (r = 0.43), although statistically significant (P < 0.01). In the case of several neoplasms e.g. Hodgkin's disease, polycythaemia vera, and adenocarcinoma of the gaster, neopterin was significantly elevated, whereas pseudouridine remained at a normal concentration. There was a positive relationship between the stage of the disease (primary focus, regional metastases, dissemination) and urinary concentration of pseudouridine in patients with adenocarcinoma of the large intestine. In the same patients the increase of neopterin excretion was noticed both in early and advanced stages, with the highest values in disseminated disease.
用于同时测定尿新蝶呤、假尿苷和肌酐的高效液相色谱法可快速评估细胞介导免疫的激活状态，以及与恶性生长相关的全身核糖体RNA + 转运RNA周转率的刺激情况。健康受试者尿中新蝶呤和假尿苷的浓度分别为：106.6±34.6 μmol/mol肌酐和19.6±5.2 mmol/mol肌酐（均值±标准差）。血液系统肿瘤患者新蝶呤排泄量的增加范围从霍奇金病的146%到非霍奇金淋巴瘤的534%，而癌症患者的增加范围从胃癌腺癌的95%到肝细胞癌的741%。假尿苷排泄量的变化则不太明显：非霍奇金淋巴瘤中为63%，膀胱癌中为120%。新蝶呤与假尿苷之间的相关系数相对较低（r = 0.43），尽管具有统计学意义（P < 0.01）。在几种肿瘤中，如霍奇金病、真性红细胞增多症和胃癌腺癌，新蝶呤显著升高，而假尿苷浓度保持正常。在患有大肠腺癌的患者中，疾病分期（原发灶、区域转移、播散）与尿中假尿苷浓度之间存在正相关关系。在同一批患者中，新蝶呤排泄量在疾病早期和晚期均有增加，在播散性疾病中达到最高值。
